US FDA approves Menveo in a new single-vial presentation to help ... - GSK
WEBOct 17, 2022 · The Menveo one-vial presentation now comes in a ready to use single vial giving healthcare providers a more convenient option. The Menveo one-vial presentation will initially be available to US federal customers, with …
GSK: CHMP Issues Positive Opinion On New Fully Liquid …
WEB1 day ago · (RTTNews) - GSK plc (GSK, GSK.L) announced the European Medicine Agency's Committee for Medicinal Products for Human Use or CHMP has recommended for use a single-vial, fully liquid presentation of ...
Novartis Receives FDA Approval of Menveo(R), a Vaccine to …
WEBFeb 22, 2010 · FDA approval of Menveo was based on a Phase III head-to-head clinical trial that compared Menveo to the other US-licensed ACWY meningococcal conjugate vaccine among subjects 11 to 55 years of age.
FDA Approves Menveo Single-Vial Presentation for Disease …
WEBOct 17, 2022 · New presentation offers health care providers with a more convenient, ready-to-use immunization option for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W.
Pfizer Announces Positive Top-Line Results from Phase 3 Trial of ...
WEBSep 15, 2022 · Phase 3 trial demonstrates that the investigational pentavalent meningococcal vaccine (MenABCWY) was well-tolerated with an acceptable safety profile and immunogenicity non-inferior to Trumenba® + Menveo® for all serogroups.
GSK announces first participant vaccinated in phase 3 clinical …
WEBAug 19, 2020 · GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that patient dosing has begun in a phase III clinical programme investigating its 5-in-1 meningitis (MenABCWY) vaccine candidate compared to licensed meningococcal vaccines, Bexsero and Menveo.
GSK’s Menveo meningococcal vaccine in new single-vial, fully …
WEB1 day ago · Data on File; List of countries where Menveo is registered and/or commercialized REF-194949; Data on File: Menveo doses distributed from 2010 to end of 2022 REF-195452; Becerra-Culqui TA, Sy LS, Ackerson BK, et al. Safety of quadrivalent meningococcal conjugate vaccine in infants and toddlers 2 to 23-months old. Vaccine. 2020; 38(2), 228–234.
WEBNew Ready-to-Use Single Vial Presentation. Menveo is a MenACWY vaccine product approved to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W. Menveo is now available in two presentations:
Single-Vial Presentation of Meningococcal Vaccine Menveo Gets …
WEBOct 17, 2022 · The FDA has approved a new ready-to-use single dose vial presentation of Menveo for active immunization against invasive meningococcal disease.
GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted …
WEBApr 16, 2024 · It offers extensive evidence of immunogenicity with a well-characterised safety profile. In the US, MENVEO is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55 years of age.
Skip to content